Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ACR | P10323 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28946942 | 0.88 | SIRT2 (0.48) | EPHX2TRPV1PPARDPPARANOTUM | |
| SCHEMBL2983289 | 0.84 | NOTUM (0.64) | EPHX2TRPV1PPARDPPARANOTUM | |
| SCHEMBL5451262 | 0.84 | EPHX2 (0.48) | EPHX2TRPV1PPARDPPARANOTUM | |
| SCHEMBL2109752 | 0.83 | RAB9A (0.45) | EPHX2NOTUMCYP3A4CYP2C19TDP1 | |
| SCHEMBL20536341 | 0.81 | NOTUM (0.47) | NOTUMTDP1L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL4060532 | 0.78 | NOTUM (0.70) | NOTUMCYP2C19TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL29197993 | 0.78 | TDP1 (0.55) | EPHX2NOTUMTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL2538472 | 0.78 | NOTUM (0.68) | NOTUMCYP2C19TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL5458474 | 0.77 | PPARD (0.48) | EPHX2TRPV1PPARDPPARANOTUM | |
| SCHEMBL2981680 | 0.76 | MAPT (0.47) | EPHX2TRPV1PPARDPPARARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417334-A | Azole derivative containing isoxazole structure, and preparation method and application thereof | 沈阳药科大学 | 2024-01-19 | — | — | CN | disclosed |
| US-8633184-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-01-21 | — | — | US | disclosed |
| US-8633184-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-01-21 | — | — | US | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7678786-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-16 | — | — | US | disclosed |
| US-7678786-B2 | Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-16 | — | — | US | disclosed |
| CN-101479008-A | Benza -oxyacetic acid derivatives as PPAR-delta agonists for raising HDL-C, lowering LDL-C and lowering cholesterol | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-08 | — | — | CN | disclosed |
| EP-2010289-A2 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007121432-A2 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007121432-A2 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | CYMABAY THERAPEUTICS, INC. | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120748-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | PPARD, PPARG, PPARA | EPHX2 2373/4885TRPV1 391/4885PPARD 1/4885 |
| US-20070244094-A1 | BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL | PPARD, PPARG, PPARA | EPHX2 2373/4885TRPV1 391/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.